Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154004 | 1.00 | HTT (0.50) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL6153937 | 0.87 | ALDH1A1 (0.50) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL6154638 | 0.87 | ALDH1A1 (0.50) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL6153940 | 0.87 | ALDH1A1 (0.50) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL2141987 | 0.81 | ALDH1A1 (0.53) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL2141982 | 0.81 | ALDH1A1 (0.53) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL6153690 | 0.79 | LMNA (0.55) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL29410261 | 0.79 | LMNA (0.55) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL6153694 | 0.79 | LMNA (0.55) | HTTALDH1A1LMNASMN1; SMN2SYK | |
| SCHEMBL29410259 | 0.79 | LMNA (0.55) | HTTLMNASMN1; SMN2SYKL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | KANEKA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1553093-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | OXER1, RCC2, CBR3 | HTT 3955/4885ALDH1A1 538/4885LMNA 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.